J Hematol

Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc

Journal website https://jh.elmerpub.com

Short Communication

Volume 14, Number 5, October 2025, pages 257-261

Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program

Tables

**Table 1.** Characteristics of the Transitioned Population of PWHA Included in the Standardized Transition to Emicizumab at the Adult Bleeding Disorders Program of British Columbia/Yukon
Characteristic	All (n = 69)
PWHA: patients with severe hemophilia A; PROBE: Patient-Reported Outcomes, Burdens and Experiences; IQR: interquartile range; HIV: human immunodeficiency virus; HCV: hepatitis C virus.
Age (years) at time of drug availability, median (IQR)	31 (26, 40)
> 2 h by car from Vancouver, n (%)	25 (36.2)
Hemophilic arthropathy (6 joints involved), n (%)
0 - 1 joints	36 (52.2)
2 - 4 joints	29 (42.0)
5 or more joints affected	4 (5.8)
HIV, n (%)	10 (14.5)
HCV (chronic diagnosis), n (%)	23 (34.3)
If HCV - cleared, n (%)	21 (95.5)
Filled out EQ5D/PROBE survey, n (%)	52 (75.4)
Composite EQ5D, median (IQR)	0.854 (0.714, 0.942)
Composite PROBE score, median (IQR)	0.791 (0.650, 0.907)

**Table 2.** Median Time to Emicizumab Transition in the Standardized Transition Program at the Adult Bleeding Disorders Program of British Columbia/Yukon
Transition time (months)	N	Minimum	Maximum	Median	IQR 25%	IQR 75%
IQR: interquartile range.
Early	28	0	9	7	4.5	8
Late	41	10	21	12	11	14
All	69	0	21	10	7	13

**Table 3.** Regression Coefficients (95% CI) for the Outcome, Months to Transition From When Emicizumab Was Available
Variable	Regression coefficient	95% confidence limits	P value
CI: confidence interval.
Intercept	10.59	8.87, 12.31	< 0.0001
Age (years) at time of emicizumab availability	-0.15	-0.23, -0.06	0.0008
> 2 h by car from Vancouver	0.75	-1.43, 2.92	0.50
Hemophilic arthropathy (reference: 0 - 1 joints)
2 - 4 joints affected	-0.26	-2.45, 1.94	0.81
5 or more joints affected	6.50	1.84, 11.16	0.007
History of adverse events on a previous factor concentrate	-5.52	-11.94, 0.90	0.09